The principal mission of the Duke Center for AIDS Research (CFAR) is to promote the collaboration and coordination of AIDS-related research by supporting the scientific needs of the basic and clinical HIV/AIDS research community at Duke. In this competitive renewal application, the new Duke CFAR seeks to use its newly established leadership role within the Medical Center to build upon the many important accomplishments of its first 4 years in existence and, in doing so, to further expand the overall infrastructure and programmatic support that will continue to provide cost effective state of the art essential services while also serving as a catalyst for future HIV/AIDS collaborative research initiatives at Duke. The highly successful Small Grant support mechanism as well as the active recruitment of 5 new key HIV/AIDS investigators to Duke both form a solid basis in moving forward into the next funding cycle. Through a highly effective Strategic Planning process, the Duke CFAR leadership, in consultation with the Duke CFAR External Advisory Committee has identified 4 priority areas for development and support over the next 5 years, that comprise the Specific Aims for this proposal and include 1) creation of an AIDS-associated malignancies basic and clinical research program at Duke in collaboration with the Duke Comprehensive Cancer Institute (DCCI), 2) development and support of a comprehensive clinical database and linked specimen repository, 3) programmatic focus on HIV pathogenesis and elimination of viral reservoirs through targeted RFAs and faculty recruitment support, and 4) full engagement of the human genomics leadership on campus through integration with the Duke CFAR. The joint CFAR-DCCI initiative for Aim 1 is further substantiated by philanthropic matching funds made available by the DCCI Director. During the initial year of new funding, the Duke CFAR service Cores will begin operating as 'partial'shared resources supported by discounted service fees and reduced CFAR investment, thus freeing funds for use in further expansion of the CFAR Cores and services as emerging needs and opportunities arise. In addition to its overall infrastructure support, the new Duke CFAR is now firmly entrenched in a highly-recognized leadership position at Duke and occupies an all important 'seat at the table'in the critical decision-making processes within the Medical Center. The CFAR leadership looks forward to providing enhanced services and support to the Duke HIV/AIDS research community in conjunction with the next 5 years of NIH funding.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI064518-08
Application #
8313674
Study Section
Special Emphasis Panel (ZAI1-JBS-A (J1))
Program Officer
Namkung, Ann S
Project Start
2005-07-15
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2012
Total Cost
$1,604,275
Indirect Cost
$574,289
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Gichane, Margaret W; Sullivan, Kristen A; Shayo, Aisa M et al. (2018) Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. AIDS Care 30:701-705
Ramadhani, Habib O; Muiruri, Charles; Maro, Venance P et al. (2018) Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS Behav 22:1671-1678
Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2018) Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana. Pediatr Infect Dis J 37:1176-1183
Ramos, Julia V; Mmbaga, Blandina T; Turner, Elizabeth L et al. (2018) Modality of Primary HIV Disclosure and Association with Mental Health, Stigma, and Antiretroviral Therapy Adherence in Tanzanian Youth Living with HIV. AIDS Patient Care STDS 32:31-37
Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:
Sikkema, Kathleen J; Choi, Karmel W; Robertson, Corne et al. (2018) Development of a coping intervention to improve traumatic stress and HIV care engagement among South African women with sexual trauma histories. Eval Program Plann 68:148-156
Watt, Melissa H; Cichowitz, Cody; Kisigo, Godfrey et al. (2018) Predictors of postpartum HIV care engagement for women enrolled in prevention of mother-to-child transmission (PMTCT) programs in Tanzania. AIDS Care :1-12
Itell, Hannah L; McGuire, Erin P; Muresan, Petronella et al. (2018) Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine 36:5600-5608
Wiehe, Kevin; Bradley, Todd; Meyerhoff, R Ryan et al. (2018) Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host Microbe 23:759-765.e6
McGuire, Erin P; Fong, Youyi; Toote, Christopher et al. (2018) HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. J Virol 92:

Showing the most recent 10 out of 488 publications